References of "Beckers, Albert"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailExpression of somatostatin receptor SST4 in human placenta and absence of octreotide effect on human placental growth hormone concentration during pregnancy.
Caron, Philippe; Buscail, Louis; Beckers, Albert ULg et al

in Journal of Clinical Endocrinology and Metabolism (1997), 82(11), 3771-3776

In pregnancy, the human placenta GH acts as a growth-promoting hormone and appears to be the main stimulator of insulin-like growth factor I (IGF-I) secretion. In a woman with a TSH-secreting macroadenoma ... [more ▼]

In pregnancy, the human placenta GH acts as a growth-promoting hormone and appears to be the main stimulator of insulin-like growth factor I (IGF-I) secretion. In a woman with a TSH-secreting macroadenoma, successful treatment with the somatostatin analog octreotide was conducted during the first month and the second half of pregnancy without side-effects on placental and fetal development. As observed in normal pregnancy, both serum placental GH and IGF-I levels increased throughout pregnancy and dropped sharply after delivery. In placental membranes from both treated and healthy untreated patients, we demonstrated the presence of high affinity binding sites for somatostatin-14 (Kd, 4.6 and 5.3 nmol/L; binding capacity, 1.53 and 1.35 pmol/mg protein, respectively). These receptors displayed low affinity for octreotide (IC50, 1.2-2 mumol/L), suggesting the presence of SST1 and/or SST4 receptors. We found that messenger ribonucleic acids of these two subtypes were expressed in both human placental tissue and purified human cytotrophoblast cells. Finally, the SST1-selective analog, des-AA1,2,5[D-Trp8,IAmp9]S-14 had low affinity for placental somatostatin receptors. These results argue in favor of the presence of the SST4 subtype in human placenta. At the doses administered, octreotide did not bind to placental somatostatin receptors. Our results may explain the absence of changes in both human placental GH and IGF-I concentrations that we observed during octreotide treatment. [less ▲]

Detailed reference viewed: 36 (3 ULg)
See detailEvaluation of us-guided percutaneous fine needle aspiration biopsyin thyroïd nodules
Meunier, Paul ULg; Collignon, J.; Thiry, Albert ULg et al

in International Congress of Head and neck Radiology - Abstract book (1997)

Detailed reference viewed: 23 (0 ULg)
Full Text
See detailAn epidemiological survey of 783 patients who underwent pituitary surgery in a single Centre over a 25-year periods
Beckers, Albert ULg; Petrossians, Patrick ULg; Stevenaert, Achille ULg

in 24th International Symposium on GH and growth factors in Endocrinology and Metabolism - Abstract book (1997)

Detailed reference viewed: 5 (0 ULg)
See detailSomatostatini SSTR2 and dopamine D2 receptors gene expression in Growth hormone-producing pituitary adenomas
Ronci, N.; Tabarin, A.; Beckers, Albert ULg et al

in 78th Endocrine Society Annual Meeting - Abstract book (1997)

Detailed reference viewed: 23 (0 ULg)
Peer Reviewed
See detailExpression des récepteurs somatostatinergiques SSTR2 et dopaminergiques D2 dans les adénomes somatotropes
Tabarin, A.; Ronci, N.; Carrié, F. et al

in Annales d'Endocrinologie (1997), 58(2),

Detailed reference viewed: 19 (0 ULg)
See detailCellular distribution of NSP in normal pituitary and in pituitary adenomas. Comparison with pituitary hormone expression.
Dukers, N.; Senden, N.; Timmer, E. et al

in 4th Euregional oncology meeting - abstract book (1997)

Detailed reference viewed: 4 (1 ULg)
See detailClinical and genetic aspects of MEN1 and related diseases : a 3 year experience based on the French-Belgian Study group on MEN1
Calender, A.; Murat, A.; Carpentier, B. et al

in 6th International Workshop on Multiple Endocrine Neoplasia and Von Hippel-Lindau Disease (1997)

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailSomatostatin SSTR2 and Dopamine D2 receptors gene expression in Growth Hormone-producing pituitary adenomas
Ronci, N.; Tabarin, A.; Beckers, Albert ULg et al

in Annales d'Endocrinologie (1997), 58(1),

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailThe Burden of Hypopituitarism in Adults after Pituitary Surgery
Van Roijen, L.; Beckers, Albert ULg; Stevenaert, Achille ULg et al

in Journal of Clinical Endocrinology and Metabolism (1997), 4(Suppl. B), 139-142

The burden of illness was assessed in 183 hypopituitary patients, with growth hormone deficiency, who had received pituitary surgery at the Centre Hospitalier Universitaire de Liège, Belgium. The Short ... [more ▼]

The burden of illness was assessed in 183 hypopituitary patients, with growth hormone deficiency, who had received pituitary surgery at the Centre Hospitalier Universitaire de Liège, Belgium. The Short-Form 36 (SF-36) was used to assess health status, and the Health and Labour Questionnaire was used to obtain data on production loss and reduced labout performance. Data on medical consumption were also collected. The overall response rate was 72 %. Hypopituitary patients reported a lower health status than that of the mean population in all but two dimensions of the SF-36 (bodily pain and physical functioning). A relativelu high percentage of hypopituitary patients reported being incapacitated for paid employment, and those in paid employment reported higher absence rates compared with reference data. However, while at work there was no indication that hypopituitary patients perform less well due to health problems than the average population. Healthcare costs for hypopituitary patients who had undergone pituitary surgery were higher than for the reference population. [less ▲]

Detailed reference viewed: 35 (0 ULg)
Full Text
Peer Reviewed
See detail125I-Tyr0-hCRH labelling characteristics of corticotropin-releasing hormone receptors: differences between normal and adenomatous corticotrophs.
Abs, R.; Smets, G.; Vauquelin, G. et al

in Neurochemistry International (1997), 30(3), 291-297

The presence of corticotropin-releasing hormone (CRH) receptors has been previously demonstrated in corticotrophs from normal pituitaries using a method combining immunocytochemistry and liquid emulsion ... [more ▼]

The presence of corticotropin-releasing hormone (CRH) receptors has been previously demonstrated in corticotrophs from normal pituitaries using a method combining immunocytochemistry and liquid emulsion autoradiography. The aim of this study was to compare the characteristics of the 125I-Tyr0-hCRH binding in corticotrophs from normal pituitaries (three obtained at autopsy and one obtained at surgery) with corticotrophs from pituitary adenomas (six corticotroph adenomas responsible for Cushing's disease and two silent corticotroph adenomas secreting a biologically inactive ACTH molecule). In normal corticotrophs, the larger part of the 125I-Tyr0-hCRH binding was localised in patchy conglomerates at the centre of the cell and, to a much lesser degree, in a diffuse pattern at the cell periphery. In adenomatous corticotrophs, CRH receptor expression is disturbed both quantitatively and qualitatively. Except for a minority of cells in one adenoma, all adenomatous corticotrophs showed only peripherally bound 125I-Tyr0-hCRH and no centrally localised binding. Furthermore, adenomatous corticotrophs revealed a statistically significant lower signal intensity when compared to normal corticotrophs and a strongly negative correlation was found between the labelling area in adenomatous corticotrophs and both the basal and CRH-stimulated plasma ACTH levels. These findings suggest defective processing of CRH receptors and could be relevant to the sustained ACTH secretion by adenomatous corticotrophs in Cushing's disease and, more generally, provide an explanation to its pathology. The silent corticotrophs secreting a biologically inactive ACTH molecule were characterised by a very faint signal intensity, although present on almost every cell. [less ▲]

Detailed reference viewed: 50 (1 ULg)
See detailLes adénome gonadotropes : Stratégie diagnostique et thérapeutique
Beckers, Albert ULg

Scientific conference (1996, November)

Detailed reference viewed: 3 (0 ULg)
See detailThyroïde et grossesse
Beckers, Albert ULg

Scientific conference (1996, October)

Detailed reference viewed: 5 (0 ULg)
See detailLes processus expansifs endosellaires non adénomateux
Beckers, Albert ULg

Scientific conference (1996, September)

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailPresurgical Octreotide: Treatment in Acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Metabolism : Clinical and Experimental (1996), 45(8 Suppl. 1), 72-4

One hundred seventy-two acromegalics who were operated on using the trans-sphenoidal approach underwent long-term follow-up evaluation. Sixty-four received 100 micrograms octreotide subcutaneously three ... [more ▼]

One hundred seventy-two acromegalics who were operated on using the trans-sphenoidal approach underwent long-term follow-up evaluation. Sixty-four received 100 micrograms octreotide subcutaneously three times daily: for 3 to 6 weeks before surgery in 14 patients (group 1); and for 3 to 9 months in 41 and for 13 to 39 months in nine (n = 50, group 2). In 18 group 2 patients, the dose was increased stepwise to 500 micrograms three times daily because of incomplete suppression of growth hormone (GH)/insulin-like growth factor-1 (IGF-1). Tumor shrinkage was seen in 60% within 3 weeks, being nearly maximal by 3 to 4 months. More group 2 patients had greater than 25% tumor shrinkage (14 of 48 v 1 of 14 in group 1). Clinical response was excellent or good in 89%. Decrease in soft-tissue swelling and weight loss, and improved vitality, performance, carbohydrate metabolism, and cardiovascular function, facilitated anesthetic and surgical management; tumor removal was easy in virtually all cases. In all 64 patients, GH levels decreased by > or = 50%, and to < 2 micrograms/L in three of 14 patients initially and 25 of 50 patients after more prolonged treatment. IGF-1 levels decreased to normal in seven of 14 group 1 and 31 of 50 group 2 patients. Light and electron microscopy showed that adenomatous tissue exposed to octreotide had lysosomal accumulation, amyloid deposition, mild to moderate perivascular fibrosis, and moderate size reduction in both cytoplasmic and nuclear areas, with virtually no cellular complications. Remission with enclosed adenomas was greater (p < .05) than for the 108 patients not treated with octreotide; there was no difference for invasive adenomas. Octreotide use for 3 to 4 months before surgery can be recommended. [less ▲]

Detailed reference viewed: 39 (1 ULg)
See detailPathologies hypophysaires
Beckers, Albert ULg

Scientific conference (1996, April 23)

Detailed reference viewed: 4 (0 ULg)
See detailLes adénomes hypophysaires gonadotropes
Beckers, Albert ULg

Scientific conference (1996, March 03)

Detailed reference viewed: 5 (0 ULg)
See detailAspect diagnostic du nodule thyroïdien isolé
Beckers, Albert ULg

Scientific conference (1996, January 20)

Detailed reference viewed: 8 (0 ULg)
See detailCabergoline, a new long-acting dopamine agonist, in the treatment of acromegaly
Abs, R.; Verhelst, J.; Verbessem, G. et al

in 10th international Congress of Endocrinology - Abstract book (1996)

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailLes adénomes gonadotropes
Beckers, Albert ULg; Stevenaert, Achille ULg

in Revue Française d'Endocrinologie Clinique, Nutrition, et Métabolisme (La) (1996), 37(4-5), 299-305

Les adénomes hypophysaires gonadotropes qui sont parmi les plus fréquents, ont été identifiés récemment; on estime aujourd'hui qu'environ 80 % des adénomes hypophysaires dits non-sécrétants sont en fait ... [more ▼]

Les adénomes hypophysaires gonadotropes qui sont parmi les plus fréquents, ont été identifiés récemment; on estime aujourd'hui qu'environ 80 % des adénomes hypophysaires dits non-sécrétants sont en fait gonadotropes. Étant donné l'absente de symptomatologie spécifique, ils ne sont souvent reconnus que lorsqu'ils sont volumineux, ayant déjà entraîné un syndrome neurologique, une compression du chiasma optique. Dans la plupart des cas il est possible de les identifier grâce aux produits de sécrétion ou encore par méthodes d'immunohistochimie ou encore par la détection de l'ARN messager correspondant aux sous-unités hormonales. Le traitement reste essentiellement neuro-chirurgical (chirurgie trans-sphénoidale) car, dans la plupart des cas, les agonistes dopaminergiques et les analogues agonistes ou antagonistes de GnRH sont inefficaces. [less ▲]

Detailed reference viewed: 27 (0 ULg)